Literature DB >> 10537385

Pneumocystis carinii pneumonia: a clinical review.

A Wilkin1, J Feinberg.   

Abstract

Pneumocystis carinii pneumonia (PCP) is an opportunistic infection that occurs in immunosuppressed populations, primarily patients with advanced human immunodeficiency virus infection. The classic presentation of nonproductive cough, shortness of breath, fever, bilateral interstitial infiltrates and hypoxemia does not always appear. Diagnostic methods of choice include sputum induction and bronchoalveolar lavage. The drug of choice for treatment and prophylaxis is trimethoprim-sulfamethoxazole, but alternatives are often needed because of adverse effects or, less commonly, treatment failure. Adjunctive corticosteroid therapy improves survival in moderate to severe cases. Complications such as pneumothorax and respiratory failure portend poorer survival. Prophylaxis dramatically lowers the risk of disease in susceptible populations. Although PCP has declined in incidence in the developed world as a result of prophylaxis and effective antiretroviral therapy, its diagnosis and treatment remain challenging.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10537385

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  11 in total

Review 1.  Update on the diagnosis and treatment of Pneumocystis pneumonia.

Authors:  Eva M Carmona; Andrew H Limper
Journal:  Ther Adv Respir Dis       Date:  2010-08-24       Impact factor: 4.031

2.  Lipophilic antifolate trimetrexate is a potent inhibitor of Trypanosoma cruzi: prospect for chemotherapy of Chagas' disease.

Authors:  Olga Senkovich; Vandanajay Bhatia; Nisha Garg; Debasish Chattopadhyay
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

3.  Apical Pneumocystis jiroveci as an AIDS defining illness: A case report illustrating a change in the paradigm.

Authors:  Kyle Pfeifer; Vivek Kalra; Adeniran Adebowale; Manisha Juthani-Mehta; Myung Soo-Shin
Journal:  J Radiol Case Rep       Date:  2014-11-30

4.  Pneumocystis S-adenosylmethionine transport: a potential drug target.

Authors:  Oscar Perez-Leal; Camilo Moncada; Allen B Clarkson; Salim Merali
Journal:  Am J Respir Cell Mol Biol       Date:  2011-06-03       Impact factor: 6.914

5.  Development and evaluation of a molecular viability assay for Pneumocystis carinii.

Authors:  N Maher; S Vermund; M Lasbury; C Lee; M Bartlett; T R Unnasch
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

6.  Action of deferoxamine against Pneumocystis carinii.

Authors:  A B Clarkson; D Turkel-Parrella; J H Williams; L C Chen; T Gordon; S Merali
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

7.  PCR diagnosis of Pneumocystis carinii on sputum and bronchoalveolar lavage samples in immuno-compromised patients.

Authors:  Somchai Pinlaor; Piroon Mootsikapun; Porntip Pinlaor; Anakapong Phunmanee; Vichit Pipitgool; Paiboon Sithithaworn; Worawan Chumpia; Jiraporn Sithithaworn
Journal:  Parasitol Res       Date:  2004-09-01       Impact factor: 2.289

8.  Effect of prednisone on the pharmacokinetics of the integrase inhibitor dolutegravir.

Authors:  Ivy H Song; Julie Borland; Shuguang Chen; Paul Savina; Amanda F Peppercorn; Stephen Piscitelli
Journal:  Antimicrob Agents Chemother       Date:  2013-07-01       Impact factor: 5.191

9.  Autopsy findings in diabetic patients: a 27-yr clinicopathologic study with emphasi on opportunistic infections and cancers.

Authors:  King-Yin Lam
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

10.  A young man with myelosuppression caused by clindamycin: a case report.

Authors:  Manuel Polanco Morales; Anna Paola Thome Carvallo; Karla Adriana Bautista Espinosa; Edgar Enrique Meza Murillo
Journal:  J Med Case Rep       Date:  2014-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.